AcquisitionsMay 5, 2026, 04:08 PM
Neurocrine to Acquire Soleno for $2.9B; Q1 Sales Up 44% to $811M
AI Summary
Neurocrine Biosciences announced its first-quarter 2026 financial results, reporting total net product sales of $811.0 million, a 44% increase year-over-year. Concurrently, the company entered a definitive agreement to acquire Soleno Therapeutics for $2.9 billion, aiming to expand its portfolio with VYKAT™ XR for Prader-Willi syndrome. The company also initiated two new clinical studies and reaffirmed its full-year 2026 INGREZZA net sales guidance.
Key Highlights
- Agreed to acquire Soleno Therapeutics for $2.9 billion, expected to close in Q2 2026.
- Total Q1 2026 net product sales were $811.0 million, a 44% increase year-over-year.
- INGREZZA net product sales grew 20% to $656.9 million in Q1 2026.
- CRENESSITY net product sales were $153.3 million in Q1 2026.
- Q1 2026 GAAP diluted EPS was $1.91, significantly up from $0.08 in Q1 2025.
- Reaffirmed 2026 full-year INGREZZA net sales guidance of $2.7 billion to $2.8 billion.
- Cash, cash equivalents, and marketable securities totaled $2.65 billion as of March 31, 2026.